TrialMolecular pharmaceutics2025

Relative Bioavailability of Zongertinib, an Orally Administered HER2-Selective Tyrosine Kinase Inhibitor, under Fed and Fasted Conditions in Healthy Male Participants: Results from Two Randomized, Open-Label, Crossover Studies.

Hélène Pereira et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.